Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Protocols

• Publication date

  2015-12-03

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/nprot.2015.137PMID 26633129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis

  2015cited by this paper
• Antibody-Mediated Delivery of Anti–KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer

  2015cited by this paper
• In vivo shRNA screens in solid tumors

  2014cited by this paper
• First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

  2013cited by this paper
• Designing efficient and specific endoribonuclease-prepared siRNAs.

  2013cited by this paper
• A simple and rapid nonviral approach to efficiently transfect primary tissue–derived cells using polyethylenimine

  2012cited by this paper
• Antibody-drug conjugates: basic concepts, examples and future perspectives.

  2012cited by this paper
• Exosome-mediated delivery of siRNA in vitro and in vivo

  2012cited by this paper
• Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis

  2012cited by this paper
• Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.

  2012cited by this paper
• The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth

  2011cited by this paper
• Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

  2011cited by this paper
• Current progress of siRNA/shRNA therapeutics in clinical trials

  2011cited by this paper
• The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.

  2010cited by this paper
• Novel siRNA Delivery System to Target Podocytes In Vivo

  2010cited by this paper
• Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-xL

  2010cited by this paper
• T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice

  2008cited by this paper
• A simple protocol for paraffin‐embedded myelin sheath staining with osmium tetroxide for light microscope observation

  2008cited by this paper
• Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1

  2007cited by this paper
• Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies

  2007cited by this paper
• Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.

  2007cited by this paper
• Housing, husbandry and handling of rodents for behavioral experiments

  2006cited by this paper
• Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

  2005cited by this paper
• Retinal pigmented epithelium determination requires the redundant activities of Pax2 and Pax6

  2003cited by this paper
• Cetuximab (Imclone/Merck/Bristol-Myers Squibb).

  2002cited by this paper
• Monoclonal antibody αIR‐3 inhibits non‐small cell lung cancer growth in vitro and in vivo

  1996cited by this paper
• Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo.

  1996cited by this paper
• Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding.

  1990cited by this paper

• Research Progress of Antibody-Oligonucleotide Conjugates—Feasibility Analysis of Antibody-Mediated siRNA Delivery

  2026cites this paper
• Staufen dsRNA-binding domain as modules to design bifunctional antibodies for siRNA delivery

  2026cites this paper
• Research progress of antibody coupling technique in targeted drug delivery

  2025cites this paper
• Antibody-drug conjugates (ADCs): "Smart Missiles" targeting cancer therapy.

  2025cites this paper
• Photodynamic ROS inducers delivered via electrostatic antibody targeted (ELART) nanocarriers incorporate into tumour cells and inhibit colony growth.

  2025cites this paper
• Towards targeted Cas9 (CRISPR‐Cas) delivery: Preparation of IgG antibody‐Cas9 conjugates using a split intein

  2024cites this paper
• Precision targeting in oncology: The future of conjugated drugs.

  2024cites this paper
• Bioanalytical approaches to support the development of antibody-oligonucleotide conjugate (AOC) therapeutic proteins

  2024cites this paper
• A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future

  2023cites this paper
• Antibody-siRNA conjugates (ARC): Emerging siRNA drug formulation

  2022cites this paper
• Targeted siRNA nanocarrier: a platform technology for cancer treatment

  2022cites this paper
• Emerging new therapeutic antibody derivatives for cancer treatment

  2022cites this paper
• Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo

  2022cites this paper
• Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

  2022cites this paper
• Manipulating Cell Fates with Protein Conjugates.

  2022cites this paper
• A photoresponsive antibody–siRNA conjugate for activatable immunogene therapy of cancer

  2022cites this paper
• Protamine-Based Strategies for RNA Transfection

  2021cites this paper
• Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

  2021cites this paper
• Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells.

  2021cites this paper
• Cetuximab–siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib

  2021influential citation
• Protamine for RNA Transfection: From Heparin Antagonist to RNA Delivery

  2021cites this paper
• Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA.

  2021cites this paper
• Functional differences between protamine preparations for the transfection of mRNA

  2020cites this paper
• Interleukin 23 and autoimmune diseases: current and possible future therapies

  2020cites this paper
• Generation and validation of structurally defined antibody–siRNA conjugates

  2020cites this paper
• Dual-luciferase assay and siRNA silencing for nodD1 to study the competitiveness of Bradyrhizobium diazoefficiens USDA110 in soybean nodulation.

  2020cites this paper
• Low‐density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia

  2020cites this paper
• A photoactivatable antibody–Chlorin e6 conjugate enabling singlet oxygen production for tumor-targeting photodynamic therapy

  2020cites this paper
• RNAi therapeutic and its innovative biotechnological evolution.

  2019cites this paper
• A ligand-based system for receptor-specific delivery of proteins

  2019cites this paper
• Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma

  2019cites this paper
• Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer

  2019influential citation
• KnockTF: a comprehensive human gene expression profile database with knockdown/knockout of transcription factors

  2019cites this paper
• Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents.

  2019cites this paper
• Recent Insights into Effective Nanomaterials and Biomacromolecules Conjugation in Advanced Drug Targeting.

  2019cites this paper
• Clinical advances of siRNA therapeutics

  2019cites this paper
• The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets.

  2018cites this paper
• The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs

  2018cites this paper
• Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth

  2018cites this paper
• Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells

  2018cites this paper
• Template-Catalyzed, Disulfide Conjugation of Monoclonal Antibodies Using a Natural Amino Acid Tag.

  2018cites this paper
• Mechanistic Insights into the Anti-angiogenic Activity of Trypanosoma cruzi Protein 21 and its Potential Impact on the Onset of Chagasic Cardiomyopathy

  2017cites this paper
• Immunoprotein-Mediated siRNA Delivery.

  2017cites this paper
• A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA.

  2017cites this paper
• A novel excision selection method for isolation of antibodies binding antigens expressed specifically by rare cells in tissue sections

  2017cites this paper
• Rôle et régulation de l'autophagie dans les lymphomes anaplasiques à grandes cellules ALK positifs

  2016cites this paper